PE20181487A1 - Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) - Google Patents

Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Info

Publication number
PE20181487A1
PE20181487A1 PE2018001129A PE2018001129A PE20181487A1 PE 20181487 A1 PE20181487 A1 PE 20181487A1 PE 2018001129 A PE2018001129 A PE 2018001129A PE 2018001129 A PE2018001129 A PE 2018001129A PE 20181487 A1 PE20181487 A1 PE 20181487A1
Authority
PE
Peru
Prior art keywords
apj
heteroarylhydroxypirimidinones
receptor agonists
compounds
apelin receptor
Prior art date
Application number
PE2018001129A
Other languages
English (en)
Spanish (es)
Inventor
Michael C Myers
R Michael Lawrence
Donna M Bilder
Wei Meng
Zulan Pi
Robert Paul Brigance
Heather Finlay
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20181487A1 publication Critical patent/PE20181487A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
PE2018001129A 2015-12-16 2016-12-15 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) PE20181487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16

Publications (1)

Publication Number Publication Date
PE20181487A1 true PE20181487A1 (es) 2018-09-18

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001129A PE20181487A1 (es) 2015-12-16 2016-12-15 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Country Status (21)

Country Link
US (1) US10669261B2 (https=)
EP (1) EP3390400B1 (https=)
JP (1) JP6948322B2 (https=)
KR (1) KR102742744B1 (https=)
CN (1) CN108602813B (https=)
AR (1) AR107061A1 (https=)
AU (1) AU2016372048B2 (https=)
BR (1) BR112018012112A2 (https=)
CA (1) CA3008630A1 (https=)
CL (1) CL2018001621A1 (https=)
CO (1) CO2018007221A2 (https=)
EA (1) EA036736B1 (https=)
ES (1) ES2854733T3 (https=)
HK (1) HK1255163A1 (https=)
IL (1) IL259947B (https=)
MX (1) MX380669B (https=)
PE (1) PE20181487A1 (https=)
SG (1) SG11201804674UA (https=)
TW (1) TW201725203A (https=)
UY (1) UY37026A (https=)
WO (1) WO2017106396A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196771A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン
KR102384668B1 (ko) * 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル-マイヤーズ スクイブ カンパニー 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
CZ298812B6 (cs) 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1686119B1 (en) * 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
JP2004504302A (ja) 2000-07-18 2004-02-12 ニューロジェン・コーポレーション 5−置換2−アリール−4−ピリミジノン
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2485148A1 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
MXPA05011387A (es) 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007510652A (ja) 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−4−オン化合物、組成物、および方法
JP2007518711A (ja) 2003-12-19 2007-07-12 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−4−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
PL2079707T3 (pl) 2006-10-10 2015-05-29 Proionic Gmbh Sposób wymiany 1,3-hetero-aromatycznych 2-karboksylanów z wodą
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
EP2279192B1 (en) 2008-05-28 2013-10-30 Merck Patent GmbH Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
EP2715858A1 (en) 2011-05-31 2014-04-09 Merck Patent GmbH Electrolyte formulations
SG195086A1 (en) 2011-05-31 2013-12-30 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统(湖州)有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
RU2015114772A (ru) * 2012-09-21 2016-11-10 Санофи Производные амида бензоимидазол-карбоновой кислоты в качестве модуляторов рецептора apj
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
WO2014078778A2 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
US20170015871A1 (en) 2013-11-29 2017-01-19 Proionic Gmbh Method for curing an adhesive using microwave irradiation
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
WO2016196771A1 (en) * 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
KR102384668B1 (ko) 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル-マイヤーズ スクイブ カンパニー 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト

Also Published As

Publication number Publication date
IL259947B (en) 2020-10-29
US10669261B2 (en) 2020-06-02
MX380669B (es) 2025-03-12
EP3390400A1 (en) 2018-10-24
UY37026A (es) 2017-06-30
CL2018001621A1 (es) 2018-08-03
CO2018007221A2 (es) 2018-07-19
CA3008630A1 (en) 2017-06-22
AU2016372048B2 (en) 2021-02-04
JP6948322B2 (ja) 2021-10-13
EA201891336A1 (ru) 2019-01-31
WO2017106396A1 (en) 2017-06-22
CN108602813B (zh) 2021-10-29
CN108602813A (zh) 2018-09-28
AR107061A1 (es) 2018-03-14
IL259947A (en) 2018-07-31
KR20180095577A (ko) 2018-08-27
EA036736B1 (ru) 2020-12-14
JP2018538304A (ja) 2018-12-27
EP3390400B1 (en) 2021-01-20
BR112018012112A2 (pt) 2018-12-04
AU2016372048A1 (en) 2018-08-02
SG11201804674UA (en) 2018-06-28
HK1255163A1 (zh) 2019-08-09
MX2018007155A (es) 2018-08-15
ES2854733T3 (es) 2021-09-22
TW201725203A (zh) 2017-07-16
KR102742744B1 (ko) 2024-12-12
US20180362508A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
PE20181487A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
PE20120034A1 (es) Compuestos derivados de n-fenilpirimidin-2-amina
CO2018004344A2 (es) Derivados de heterociclos bicíclicos condensados como agentes de control de plagas
AR098912A1 (es) Inhibidores de syk
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
PE20180506A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
PE20181197A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
AR096339A1 (es) Agonistas del receptor de somatostatina subtipo 4 (sstr4)
AR092827A1 (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7